EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access

NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

Bobbie J Rimel iD, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Nitya Alluri, Mark Borowsky, John Moroney, Andrea Wahner Hendrickson, Floor Backes iD, Elizabeth Swisher, Matthew Powell und 1 weitere

Cancer · 2024

DOI: 10.1002/cncr.35151 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer, 2024. Verfasst von Bobbie J Rimel und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, Cedars-Sinai Medical Center, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Agents, Endometrial Neoplasms, Indoles. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NRG Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This paper reports the efficacy of the poly (ADP‐ribose) polymerase inhibitor olaparib alone and in combination with the antiangiogenesis agent cediranib compared with cediranib alone in patients with advanced endometrial cancer.

Methods

This was open‐label, randomized, phase 2 trial (NCT03660826). Eligible patients had recurrent endometrial cancer, received at least one (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsAntineoplastic AgentsEndometrial NeoplasmsIndolesPiperazinesQuinazolinesHumansFemaleAgedNeoplasm Recurrence, LocalPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

PARP inhibitorcediranibclinical trialendometrial cancerolaparib

Substanzen

olaparibcediranibAntineoplastic AgentsPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsIndolesPiperazinesQuinazolines

Autor:innen und Institutionen

  • Division of Gynecologic Oncology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Clinical Trials Development Division, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA.
  • University of Oklahoma Health Sciences Center, Mercy Hospital Gynecologic Oncology, Oklahoma City, Oklahoma, USA.
  • Minnesota Oncology, Coon Rapids, Minnesota, USA.
  • St. Luke's Cancer Institute, Boise, Idaho, USA.

ORCID-Profile: Bobbie J Rimel, Floor Backes, Helen MacKay

Förderung

  • NCI NIH HHS
  • NRG Oncology

Zitieren

APA

Rimel, B. J., Enserro, D., Bender, D. P., Jackson, C. G., Tan, A., Alluri, N., Borowsky, M., Moroney, J., Hendrickson, A. W., Backes, F., Swisher, E., Powell, M., & MacKay, H. (2024). NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. https://doi.org/10.1002/cncr.35151

Vancouver

Rimel BJ, Enserro D, Bender DP, Jackson CG, Tan A, Alluri N, et al. NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 2024. doi:10.1002/cncr.35151

BibTeX
@article{Rimel2024,
  author = {Rimel, Bobbie J and Enserro, Danielle and Bender, David P and Jackson, Camille Gunderson and Tan, Annie and Alluri, Nitya and Borowsky, Mark and Moroney, John and Hendrickson, Andrea Wahner and Backes, Floor and Swisher, Elizabeth and Powell, Matthew and MacKay, Helen},
  title = {NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35151}
}
Kostenlos starten →